These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 419386)

  • 1. Epodyl treatment of bladder tumours.
    Nielsen HV; Thybo E
    Scand J Urol Nephrol; 1979; 13(1):59-63. PubMed ID: 419386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracavitary Epodyl for multiple non-invasive, highly differentiated bladder tumours.
    Colleen S; Ek A; Hellsten S; Lindholm CE
    Scand J Urol Nephrol; 1980; 14(1):43-5. PubMed ID: 7375840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epodyl treatment of bladder neoplasms].
    Hannestad R; Otnes B
    Tidsskr Nor Laegeforen; 1976 Jan; 96(1):25-7. PubMed ID: 1257948
    [No Abstract]   [Full Text] [Related]  

  • 4. Ureteropyeloscopic tumour treatment.
    Mathiasen H; Frimodt-Möller PC; Nielsen HV
    Scand J Urol Nephrol Suppl; 1988; 110():201-3. PubMed ID: 3187408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for bladder cancer.
    Veenema RJ; Romas NA; Fingerhut B
    Urology; 1974 Feb; 3(2):135-9. PubMed ID: 4204755
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravesical ethoglucid (Epodyl) for treatment of noninvasive bladder cancer (stage Ta).
    Larson A; Fritjofsson A
    Ups J Med Sci; 1985; 90(2):127-32. PubMed ID: 3909592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epodyl in management of noninvasive vesical neoplasms.
    SMith JM; Lane V; O'Flynn JD
    Urology; 1978 May; 11(5):474-7. PubMed ID: 675901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of Epodyl in aluminium foil cups as a cause of ineffective treatment of non-invasive bladder tumours.
    Larsen J
    Scand J Urol Nephrol; 1980; 14(3):239-42. PubMed ID: 7209431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group.
    Robinson MR; Shetty MB; Richards B; Bastable J; Glashan RW; Smith PH
    J Urol; 1977 Dec; 118(6):972-3. PubMed ID: 926278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer.
    Mufti GR; Virdi JS; Hall MH
    Br J Urol; 1990 Jan; 65(1):32-5. PubMed ID: 2310930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl.
    Fitzpatrick JM; Khan O; Oliver RT; Riddle PR
    Br J Urol; 1979 Dec; 51(6):545-8. PubMed ID: 534839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.
    Kurth KH; Schröder FH; Tunn U; Ay R; Pavone-Macaluso M; Debruyne F; de Pauw M; Dalesio O; ten Kate F
    J Urol; 1984 Aug; 132(2):258-62. PubMed ID: 6376827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of superficial bladder tumours with intravesical Epodyl.
    Riddle PR
    Br J Urol; 1973 Feb; 45(1):84-7. PubMed ID: 4690153
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of pathologic changes in the urinary epithelium on the absorption of ethoglucide (Epodyl) from the bladder].
    Lunglmayr G; Kratzik C; Mattausch M
    Wien Klin Wochenschr; 1984 Mar; 96(5):182-5. PubMed ID: 6730516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J; Kühnel W; Dona S
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors influencing survival of patients receiving intravesical epodyl.
    Riddle PR; Khan O; Fitzpatrick JM; Oliver RT
    J Urol; 1982 Mar; 127(3):430-2. PubMed ID: 7062411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ultrastructure of transitional cell carcinomas of the human urinary bladder treated with ethoglucid or mitomycin.
    Stewart RJ; Lawson AH; Weaver JP
    J Urol; 1988 Jun; 139(6):1355-8. PubMed ID: 3373614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of vesical and prostatic tumours.
    Pavone-Macaluso M
    Br J Urol; 1971 Dec; 43(6):701-8. PubMed ID: 4110519
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant chemotherapy of superficial transitional cell carcinoma: an E.O.R.T.C. randomized trail comparing doxorubicin hydrochloride, ethoglucid and TUR-alone.
    Kurth KH; Debruyne FJ; Senge T; Carpentier PJ; Riedl H; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1985; 185B():135-42. PubMed ID: 3898138
    [No Abstract]   [Full Text] [Related]  

  • 20. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
    Flamm J; Bucher A; Höltl W; Albrecht W
    J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.